The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

By A. De Luca, M. Maiello, A. D’alessio, Maria Pergameno, N. Normanno. Expert opinion on therapeutic targets, 2012

711 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/9ccb4d13c8ec132d8ddfb8aed4a38e1020ecce23

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Bahar
2. D. Kim
3. Hyun Joon Kim

Citations in the corpus

• The MAPK pathway across different malignancies: A new perspective (2014, background): “The PI3K/ AKT pathway also promotes anabolism; whereas the MAPK/ERK pathway is more active in proliferation and invasion.(5) Up-regulation of MAPK/ERK signaling occurs as a result of overexpression or aberrant activation of receptor tyrosine kinases (RTKs) or their immediate downstream targets: PI3K”
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “253 The intricate network of positive feedfor-ward and negative feedback loops in these pathways signi fi cantly in fl uences signal dynamics.”